Bey-Douglas LLC’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.46M Sell
5,936
-39
-0.7% -$39.5K 4.76% 5
2025
Q4
$6.42M Buy
5,975
+1,125
+23% +$1.08M 5.14% 7
2025
Q3
$3.7M Sell
4,850
-1,467
-23% -$1.09M 2.75% 16
2025
Q2
$4.92M Buy
6,317
+1,157
+22% +$899K 2.94% 16
2025
Q1
$4.26M Sell
5,160
-15
-0.3% -$12.5K 3.89% 12
2024
Q4
$4M Buy
5,175
+2,290
+79% +$1.9M 3.44% 15
2024
Q3
$2.56M Buy
+2,885
New +$2.59M 2.24% 18

Other funds holding LLY

Bey-Douglas LLC's LLY Position: Q1 2026 in Review

Bey-Douglas LLC reduced its Eli Lilly (LLY) stake by 0.65% in Q1 2026, selling an estimated $39.5K and leaving 5,936 shares worth $5.46M. The position accounts for 4.76% of the portfolio, ranked #5.

Bey-Douglas LLC first reported a position in LLY in Q3 2024 and has held it in 7 quarters since. The position peaked at $6.42M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Bey-Douglas LLC held 5,936 shares of Eli Lilly worth $5.46M as of Q1 2026.
  • Bey-Douglas LLC sold 39 Eli Lilly shares in Q1 2026, an estimated $39.5K.
  • Eli Lilly made up 4.76% of Bey-Douglas LLC's portfolio in Q1 2026, its #5 holding.
  • Bey-Douglas LLC first reported a position in Eli Lilly in Q3 2024 and has held it in 7 quarters since.
  • Bey-Douglas LLC's Eli Lilly position peaked at $6.42M in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Bey-Douglas LLC's 13F filing for Q1 2026, filed 12 May 2026.